A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli

A Phase II Study to Evaluate the Efficacy of Anti-Fibrin Humanized Monoclonal Antibody(DI-DD3B6/22-80B3) Fab' Fragment (ThromboView®) Conjugated With Technetium-99m in the Detection of Pulmonary Emboli

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00519506

Enrollment

Registered

2007-08-22

Start date

2007-09-30

Completion date

2008-10-31

Last updated

2009-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Keywords

Pulmonary Embolism, PE

Brief summary

The aim of the study is to determine the diagnostic accuracy of 99mTc ThromboView® SPECT imaging for the detection of acute pulmonary embolism (PE) in patients for whom there is a moderate to high clinical suspicion for PE.

Interventions

OTHERThromboView

Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Written consent by the subject to participate in the study. 2. Moderate to high pre-test probability of acute pulmonary embolism. 3. Positive D-dimer. 4. Onset of PE symptoms occurring within the last seven days. 5. Aged 18 years or older. 6. Women of childbearing potential must have a negative serum pregnancy test (β-hCG) result at the time of enrollment into the study. Both male and female participants must agree to use effective contraception for the first 30 days after administration of 99mTc ThromboView®.

Exclusion criteria

1. The subject is unwilling or unable to provide written informed consent. 2. Allergy or other contraindication to intravenous iodinated contrast media. 3. Prior exposure to murine, chimeric or humanized antibodies. 4. Illicit intravenous drug use in the past 12 months. 5. Administration of therapeutic radioiodine in the past 6 months. 6. Life expectancy less than 90 days. 7. Previous participation in the current study. 8. Current enrollment in a clinical trial involving any other investigational agent. 9. Subject is unsuitable for SPECT scanning at the study Investigator's discretion (e.g. residual detectable radioactivity within the lungs due to prior imaging studies or treatment, preceding planned administration of 99mTc ThromboView®). 10. Inability to perform CTPA or 99mTc ThromboView imaging, for any reason. 11. Renal dysfunction: calculated creatinine clearance \< 30 mL/min. 12. Hepatic dysfunction: serum transaminases ≥ 3 x upper limit of normal range. 13. Hepatic dysfunction: subject has history of chronic or currently active liver disease. 14. Current pregnancy or lactation or conception intended within three months of enrollment. 15. Subject is unsuitable for the study at the study Investigator's discretion. -

Design outcomes

Primary

Measure	Time frame
Provide estimates of the sensitivity of 99mTc ThromboView® in subjects with confirmed PE, as determined by computed tomographic pulmonary angiography (CTPA) and the specificity of 99mTc ThromboView® in subjects with PE excluded by CTPA	June 2008

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026